The author refutes the argument that clinical trials cannot keep up with the pace of development in dentistry in the U.S. because of the extremely high turnover rate or introduction of new systems. He asserts that dental material manufacturers are facing ethical consideration with regards to investment in clinical research and product launching. He criticizes regulatory bodies that control the approval of new systems to the marketplace to be used on patients.